January 30, 2009--StemCellPatents.com, an organization that covers recent news in stem cell therapeutics and has assembled the only comprehensive index of all issued U.S. stem cell patents, congratulates International Stem Cell Corporation (OTCBB: ISCO), on its recent developments, including being the first company to grow human corneal tissue from stem cells.
ISCO, the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, recently created layered human tissue from its parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa. In related news, ISCO is planning pre-clinical trials aimed at applying corneal epithelial cells grown from human tissue to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery.
ISCO's human parthenogenetic stem cells have the potential to treat human disease, yet possess key medical and ethical advantages over other kinds of stem cell products. They can be matched to common immune types and thus reduce the chance of transplant rejection among large segments of the population. Because they are created from unfertilized human eggs, they do not require the destruction of human embryos.(more)
http://www.stemcellpatents.com/news-show-363
ISCO, the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, recently created layered human tissue from its parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa. In related news, ISCO is planning pre-clinical trials aimed at applying corneal epithelial cells grown from human tissue to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery.
ISCO's human parthenogenetic stem cells have the potential to treat human disease, yet possess key medical and ethical advantages over other kinds of stem cell products. They can be matched to common immune types and thus reduce the chance of transplant rejection among large segments of the population. Because they are created from unfertilized human eggs, they do not require the destruction of human embryos.(more)
http://www.stemcellpatents.com/news-show-363